Vinson D, Molet-Benhamou L, Degboé Y, et al. - Per current guidelines, tapering of targeted therapies for rheumatoid arthritis (RA) or spondyloarthritis (SpA) patients in remission is recommended. Researchers here performed a systematical review in order to ascertain how tapering targeted therapies (bDMARDs or JAKis) influences the risk of serious infections and severe adverse events (SAEs) in cases with rheumatoid arthritis (RA) or axial SpA in remission or low disease activity state. They searched PubMed, Embase, Cochrane, until August 2019, as well as relevant databases of international conferences, and identified 1,957 studies initially. In the meta-analysis, they included 13 controlled trials (9 RA and 4 SpA trials) yielding data of 1,174 patient-years in the tapering group vs 1,086 patient-years in the usual care group. Outcomes revealed that tapering targeted therapies leads to no change in serious infection risk, SAEs, cardiovascular adverse events, malignancies. Hence they emphasize to make efforts to taper targeted therapies for efficiency and financial advantages.